Pertussis: Challenges Today and for the Future

PLoS Pathogens

Volumn 9, Issue 7, 2013, Pages

  Cherry, James D ^a,b  

^a MATTEL CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACELLULAR VACCINE; HEMAGGLUTININ; PERTACTIN; PERTUSSIS TOXIN; PERTUSSIS VACCINE;

ARTICLE; BACTERIAL INFECTION; BORDETELLA PERTUSSIS; CILIATED EPITHELIUM; COUGHING; FEVER; FIMBRIA; HUMAN; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; LEUKOCYTE; LEUKOCYTOSIS; LYMPHOCYTOSIS; MORTALITY; NONHUMAN; PERTUSSIS; POLYMERASE CHAIN REACTION; PULMONARY HYPERTENSION; VIRUS INFECTION;

EID: 84884758565     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003418     Document Type: Article

References (27)

1. Cherry JD, Heininger U (2009) Pertussis and other Bordetella infections. In: Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan S, editors. Feigin and Cherry's textbook of pediatric infectious diseases. 6th edition. Philadelphia, PA: WB Saunders Co. pp. 1683-1706.
2. Holmes WH (1940) Whooping-cough, or pertussis. In: Holmes WH, editor. Bacillary and rickesttsial infections acute and chronic- a textbook. New York: The MacMillan Company. pp. 395-414.
3. Lapin JH (1943) Whooping cough. Springfield, IL: Charles C. Thomas Publishing. 112-122 p.
4. Mattoo S, Cherry JD, (2005) Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 18: 326-382.
5. Cherry JD, Paddock CDJ (2013) What Bordetella pertussis toxins and other proteins do and do not do in the pathogenesis of pertussis. Presented at: Pediatric Academic Scoieties Annual Meeting; May 2013; Washington, DC.
6. Murray EL, (2013) Characteristics of severe Bordetella pertussis infection among infants ≤90 days of age admitted to pediatric intensive care units- Southern California, September 2009-June 2011. J Pediatric Infect Dis Soc pp. 1-6.
7. Paddock CD, Sanden GN, Cherry JD, Gal AA, Langston C, et al. (2008) Pathology and pathogenesis of fatal Bordetella pertussis infection in infants. Clin Infect Dis 47: 328-338.
8. Cherry JD, (2003) The science and fiction of the "resurgence" of pertussis. Pediatrics 112: 405-406.
9. Cherry JD, (2005) The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection. Pediatrics 115: 1422-1427.
10. Cherry JD, (2010) The present and future control of pertussis. Clin Infect Dis 51: 663-667.
11. Cherry JD, (2012) Epidemic pertussis in 2012-the resurgence of a vaccine-preventable disease. N Engl J Med 367: 785-787.
12. Cherry JD, (2012) Why do pertussis vaccines fail? Pediatrics 129: 968-970.
13. Cherry JD, Olin P, (1999) The science and fiction of pertussis vaccines. Pediatrics 104: 1381-1383.
14. World Health Organization (1991) WHO meeting on case definition of pertussis: report of the meeting.Geneva, 10-11, Jan 1991. MIM/EPI/PERT/91.1.
15. Cherry JD, Heininger U, Stehr K, Christenson P, (1998) The effect of investigator compliance (observer bias) on calculated efficacy in a pertussis vaccine trial. Pediatrics 102: 909-912.
16. Cherry JD, Gornbein J, Heininger U, Stehr K, (1998) A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 16: 1901-1906.
17. Storsaeter J, Hallander HO, Gustafsson L, Olin P, (1998) Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 16: 1907-1916.
18. Cherry JD, Heininger U, Richards DM, Storsaeter J, Gustafsson L, et al. (2010) Antibody response patterns to Bordetella pertussis antigens in vaccinated (primed) and unvaccinated (unprimed) young children with pertussis. Clin Vaccine Immunol 17: 741-747.
19. Preston NW, (1965) Effectiveness of pertussis vaccines. Br Med J 2: 11-13.
20. Schmidtke AJ, Boney KO, Martin SW, Skoff TH, Tondella ML, et al. (2012) Population diversity among Bordetella pertussis isolates, United States, 1935-2009. Emerg Infect Dis 18: 1248-1255.
21. Mooi FR, van Loo IH, van Gent M, He Q, Bart MJ, et al. (2009) Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerg Infect Dis 15: 1206-1213.
22. Queenan AM, Cassiday PK, Evangelista A, (2013) Pertactin-negative variants of Bordetella pertussis in the United States. N Engl J Med 368: 583-584.
23. Weiss AA, Patton AK, Millen SH, Chang SJ, Ward JI, et al. (2004) Acellular pertussis vaccines and complement killing of Bordetella pertussis. Infect Immun 72: 7346-7351.
24. Olin P, Gustafsson L, Rasmussen F, Hallander HO, Hejibel H,et al. (1997) Efficacy trial of acellular pertussis vaccines; trial II. 1 Jan 1997. Swedish Institute for Infectious Disease Control. pp. 52-54.
25. Liko J, Robison SG, Cieslak PR, (2013) Priming with whole-cell versus acellular pertussis vaccine. N Engl J Med 368: 581-582.
26. Sheridan SL, Ware RS, Grimwood K, Lambert SB, (2012) Number and order of whole cell pertussis vaccines in infancy and disease protection. JAMA 308: 454-456.
27. Mallory FB, Hornor AA, (1912) Pertussis: The histological lesion in the respiratory tract. J Med Res 27: 115-124.